FIGURE 2 from First-line Avelumab plus Chemotherapy in Patients with Advanced Solid Tumors: Results from the Phase Ib/II JAVELIN Chemotherapy Medley Study

Pharmacokinetics of avelumab over time following administration of 800 and 1,200 mg every 3 weeks in the urothelial carcinoma and NSCLC cohorts. A, Serum avelumab Ctrough by visit. B, Serum avelumab Cmax by visit. C, Serum avelumab concentrations on day 15 visit. Horizontal black line within each box depicts the median, and upper and lower lines depict the third (Q3) and first (Q1) quantiles, respectively. Upper and lower error bars represent Q3 + 1.5 × IQR and Q1 – 1.5 × IQR, respectively. Dashed line represents median, and dotted lines represent 5th and 95th percentiles of historical steady state Ctrough (A and C) or Cmax (B) from population pharmacokinetic model–based simulations of avelumab 10 mg/kg every 2 weeks in monotherapy (1, 2). IQR, interquartile range.